Clinical trials: Cardiology
Ventricular Tachycardia (VT)
Safety and Performance Assessment of the Sphere-9™ Catheter and Affera™ Ablation System for the Treatment of Ventricular Tachycardia (Sphere-9 VT EFS)
Sphere-9 VT EFS is a prospective, multi-center, non-randomized, unblinded feasibility study. Adult subjects with recurrent, sustained, scar-related monomorphic ventricular tachycardia will be enrolled and treated with the…
- Trial name
- NCT06703489
- Testing
- Sphere-9 Catheter with the Affera Mapping and Ablation System
- Where
- 6 sites in United States
- Volunteers
- 60 people
- Sponsor
- Medtronic Cardiac Ablation Solutions
Hypertension (HTN)
Actions to Decrease Disparities in Risk and Engage in Shared Support for Blood Pressure Control (ADDRESS-BP) in Blacks
To use practice facilitation (PF) + community health worker (CHW) facilitation as a practical and sustainable implementation strategy to support the implementation and evaluation of three multi-level evidence-based interventions…
- Trial name
- NCT05208450
- Testing
- Practice support And Community Engagement (PACE)
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- NYU Langone Health
Chronic Venous Insufficiency
National Varicose Vein Study - Portugal
The National Varicose Vein Study is a cross-sectional, multicenter, observational study. The primary goal is to evaluate the 30 days outcome of the conventional great saphenous vein surgery (stripping) in the treatment of the…
- Trial name
- NCT05625074
- Testing
- Conventional surgery for great saphenous vein insufficiency
- Where
- Portugal
- Volunteers
- 250 people
- Sponsor
- Universidade do Porto
Ankle Brachial Index
Ankle Brachial Index Combined With Serum Uric Acid Levels Improve Prediction All Cause Mortality and Cardiovascular Mortality in the Elderly Chinese Population
Peripheral arterial disease (PAD) is a common clinical manifestation of the systemic atherosclerotic process, and the ankle brachial index (ABI) is an ideal tool to diagnose PAD.
- Trial name
- abilities (NCT03616418)
- Testing
- antiplatelet drugs;statins;antihypertensive drugs
- Volunteers
- 3,026 people, healthy volunteers welcome
- Sponsor
- Shanghai 10th People's Hospital
Myocardial Infarction, No-Reflow Phenomenon
Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI
The patients with acute myocardial infarction (AMI) present high mortality and morbidity rate,even treated with stenting in the blocked heart vessels. The appearance of no-reflow is common after re-opening of the blocked vessel.
- Trial name
- NCT02233790
- Testing
- Ticagrelor, Clopidogrel
- Where
- China
- Volunteers
- 600 people
- Sponsor
- First Hospital of China Medical University
Chronic Obstructive Lung Disease (COLD), Heart Failure
Reforça't: A Community, Social, and Healthcare Program for Patients With Cardiorespiratory Conditions Upon Hospital Discharge
The goal of this randomized clinical trial is to determine whether an interdisciplinary, community-based intervention can reduce 30-day hospital readmissions and improve functional outcomes in patients aged 65 or older with…
- Trial name
- R't (NCT06897410)
- Testing
- Interdisciplinary Program for Post-Hospitalization / Hospital at home Management and Long-Term Outcomes in Older Adults with Chronic Cardiorespiratory Condition
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Corporació de Salut del Maresme i la Selva
Heart Attack, NSTEMI
A Phase 2 Trial of AMI MultiStem® Therapy in Subjects With Non-ST Elevation Acute Myocardial Infarction
This is a double-blind, sham-controlled clinical study to evaluate the safety and feasibility of AMI MultiStem therapy in subjects who have had a heart attack (Non-ST elevation MI).
- Trial name
- MI-NSTEMI (NCT02277613)
- Testing
- AMI MultiStem cells
- Where
- 11 sites in United States
- Volunteers
- 34 people
- Sponsor
- Healios K.K.
Macular Edema, Branch Retinal Vein Occlusion
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Branch retinal vein occlusion is a leading cause of vision loss. Treatment with ranibizumab (vascular endothelial growth factor (VEGF) inhibitor) on a monthly basis has been associated with improved vision results.
- Trial name
- Revolution (NCT01247220)
- Testing
- Ranibizumab, Peripheral Laser
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Retina Associates of Florida, P.A.
Atrial Fibrillation
A Registry Based Collaborative to Measure Efficiency, Effectiveness, and Safety of Farapulse PFA Technology for AF
The DISRUPT-AF Registry is an observational, prospective, multi-center, non-randomized, real-world registry designed to obtain clinical experience with the Farapulse Pulsed Field Ablation System for the treatment of atrial…
- Trial name
- DISRUPT-AF (NCT06335082)
- Testing
- Pulsed Field Ablation
- Where
- 36 sites in United States
- Volunteers
- 10,000 people
- Sponsor
- Heart Rhythm Clinical and Research Solutions, LLC
Antineutrophil Cytoplasmic Antibody-associated Vasculitis
A Study to Evaluate Avacopan in Participants With ANCA-associated Vasculitis
The primary objective of this study is to evaluate the long-term safety of avacopan in participants with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
- Trial name
- AVASET (NCT06072482)
- Testing
- Avacopan, Standard of Care
- Where
- 83 sites in United States, Czechia and 5 more
- Volunteers
- 300 people
- Sponsor
- Amgen
Atrial Fibrillation
MARSHALL PLAN Vs. Pulmonary Veins Isolation Monocentric Trial
In ablation strategy for persistent Atrial Fibrillation (PsAF), ablation limited to Pulmonary Vein (PV) isolation is the most straightforward approach but the result give only 50% of arrhythmia free follow-up.
- Trial name
- PLAN-MARSHALL (NCT04206982)
- Testing
- Destruction of Marshall bundles, Pulmonary veins isolation, Linear ablation in the left and right atria
- Where
- France
- Volunteers
- 120 people
- Sponsor
- University Hospital, Bordeaux
Traumatic Brain Injury, Intracranial Hemorrhages
Andexanet Alfa for Reversal of Factor Xa Inhibitors in Traumatic Brain Injury: A Retrospective Single-Centre Study
Elderly patients on direct oral anticoagulants (DOACs), specifically factor Xa (FXa) inhibitors such as apixaban and rivaroxaban are at elevated risk of haematoma expansion following traumatic brain injury (TBI).
- Trial name
- AA-TBI (NCT07898982)
- Where
- Slovenia
- Volunteers
- 34 people
- Sponsor
- University Medical Centre Ljubljana
Atrial Fibrillation, Deep Vein Thrombosis
Randomized Trial of Interventions to Improve Warfarin Adherence
The purpose of this research study is to see if a lottery which provides the opportunity to win money, a reminder system using a "Med-eMonitor", or the combination of both might be useful in helping patients to achieve better…
- Conditions
- Atrial Fibrillation, Deep Vein Thrombosis, Dilated Cardiomyopathies
- Trial name
- WIN3 (NCT00904982)
- Testing
- Financial Incentive and Med-eMonitor, 2Med-eMonitor
- Where
- 2 sites in United States
- Volunteers
- 268 people
- Sponsor
- University of Pennsylvania
Single-ventricle, Posttraumatic Stress Disorder
The PaTHS Descriptive Correlational Longitudinal Study
The primary objective of this study is to measure parent's post-traumatic stress before and after their infant's second palliative heart surgery for single ventricle congenital heart disease.
- Conditions
- Single-ventricle, Posttraumatic Stress Disorder, Psychosocial Impairment
- Trial name
- PaTHS (NCT04785482)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Children's Mercy Hospital Kansas City
Cardiovascular Disease
Simplified Cardiovascular Management Study
The goal of this study is to develop, pilot test, and evaluate a highly simplified but guideline-based program for cardiovascular management for application in resource-scarce settings.
- Trial name
- SimCard (NCT01503814)
- Testing
- Simplified cardiovascular disease management
- Where
- 3 sites in China, India
- Volunteers
- 2,086 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Stroke
Effect Of Breather On Pulmonary And Physical Function In Post Stroke Survivors
Stroke is the second major cause of death and disability worldwide with over 13 million new cases annually. Egypt, a low-middle-income country, is the most populated nation in the Middle East with a high overall crude prevalence…
- Trial name
- NCT05678816
- Testing
- BREATHER, physiotherapy prgramme for rehabilitation of stroke patients
- Where
- 2 sites in Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
Chronic Kidney Disease
Ultrasound to Predict Steal-Syndrome After Arteriovenous-Fistula Creation (UPSAC - Trial)
The purpose of this study is to analyze and identify pre-, intra-, and post- operative parameters that predict Steal-Syndrome with distal malperfusion after Arterio-Venous Fistulas (AVF) as primary endpoint.
- Trial name
- UPSAC (NCT01468506)
- Where
- United States
- Sponsor
- Baptist Health South Florida
Myocardial Infarction
Sevoflurane and Percutaneous Coronary Intervention by Stent
Increase in CK-MB after percutaneous coronary angioplasty more than 100% of baseline can represents a problem to the patients resulting in increase of morbidity and mortality.
- Trial name
- NCT02671084
- Testing
- sevoflurane
- Where
- Brazil
- Volunteers
- 701 people
- Sponsor
- Instituto Dante Pazzanese de Cardiologia
Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
The purpose of this study is to find out if the combination of pirtobrutinib, venetoclax, and rituximab is an effective treatment for participants with Waldenström's macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL)
- Trial name
- NCT07231952
- Testing
- Pirtobrutinib, Venetoclax, Rituximab
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Essential Hypertension
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
This study will assess the efficacy and safety of the single pill combination of Aliskiren and Amlodipine in patients with moderate hypertension not adequately responding to a single pill combination of Olmesartan and Amlodipine.
- Trial name
- AWESOME (NCT01113047)
- Testing
- Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
- Where
- Germany
- Volunteers
- 347 people
- Sponsor
- Novartis